These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 11366740)

  • 21. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
    Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
    Zeldin RK; Petruschke RA
    J Antimicrob Chemother; 2004 Jan; 53(1):4-9. PubMed ID: 14657084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taking a break when all else fails.
    Gilden D
    GMHC Treat Issues; 1999 Apr; 13(4):1-3. PubMed ID: 11366972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amprenavir approved.
    STEP Perspect; 1999; 99(2):8. PubMed ID: 11366753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
    Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
    Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crossing the waters to the post-HAART era (or Jeanette meets Amalia).
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Dec; 5(12):12-23, 28-33, 37-43, 47-51. PubMed ID: 11367348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits and concerns of simplification strategies in HIV-infected patients.
    Negredo E; Bonjoch A; Clotet B
    J Antimicrob Chemother; 2006 Aug; 58(2):235-42. PubMed ID: 16807250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
    Bucher HC; Young J; Battegay M
    J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Follow PI doses or don't prescribe them at all, researchers say.
    AIDS Alert; 1997 Apr; 12(4):37-40. PubMed ID: 11364144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily therapies.
    Carey D
    J HIV Ther; 2003 Feb; 8(1):7-11. PubMed ID: 12840708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
    Justesen US
    Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the road with protease inhibitors.
    Cadman J
    GMHC Treat Issues; 1998 May; 12(5):10-2. PubMed ID: 11365475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hit hard early or delay? New drugs cloud options.
    AIDS Alert; 1996 Apr; 11(4):40-1. PubMed ID: 11363401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug interactions, toxicities, dosages: trials and tribulations and cocktails.
    Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard dosing schedule for anti-HIV drugs.
    Proj Inf Perspect; 1998 Dec; (26):12-3. PubMed ID: 11366489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosing regimens: what's it all about, Alfie?
    Res Initiat Treat Action; 1998 Feb; 4(1):15. PubMed ID: 11365216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indinavir (Crixivan): new packaging and strength.
    Res Initiat Treat Action; 1999 Apr; 5(2):33. PubMed ID: 11366284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease inhibitors and diabetes: a growing problem.
    Colvin R
    Common Factor; 1997 Nov; (No 11):8. PubMed ID: 11364847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.